Search

Your search keyword '"Garassino M"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Garassino M" Remove constraint Author: "Garassino M" Publisher elsevier Remove constraint Publisher: elsevier
42 results on '"Garassino M"'

Search Results

1. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Catalog

Books, media, physical & digital resources

3. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status

4. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671).

5. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.

6. NTRK gene fusion testing and management in lung cancer.

7. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review.

9. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.

10. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.

11. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

12. Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.

13. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.

14. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.

15. Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM).

16. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.

17. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey.

18. Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?

19. The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate.

20. Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy.

21. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.

22. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.

23. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.

24. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.

25. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.

27. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

28. Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

29. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

30. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.

31. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

32. Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells.

33. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.

34. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.

35. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

36. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.

37. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.

39. Predicting response of molecular targeted therapies: a still possible challenge?

40. Reversible palpebral ptosis following oxaliplatin infusion.

41. New anti-emetic treatments.

42. New strategies in colon cancer adjuvant therapy.